Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high ...

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout. The novel formulation of the stalwart ...

This Research Topic seeks to tackle the pressing issue of variability in pathology practices concerning radical cystectomy (RC) specimens. Despite existing ...

British researchers have discovered that the virus can specifically trigger DNA damage in tissue in the bladder.

Johnson & Johnson's Inlexzo shows promising survival rates in BCG-unresponsive NMIBC patients. Read more here.

Only 18% of NMIBC patients say they have frequent discussions with their HCPs about all available procedures/treatment options for NMIBC during most or every visit, yet most patients (92%) say they ...

Gene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as ...

The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed ...

A new U.S. survey conducted by The Harris Poll on behalf of ImmunityBio, Inc. ( NASDAQ: IBRX) reveals that many people living with non-muscle invasive bladder cancer (NMIBC) feel left out of critical ...

The Society of Urologic Oncology (SUO) and Ferring Pharmaceuticals today announced the SUO NMIBC (non-muscle invasive bladder cancer) Fellows Research Grant, created to support outstanding clinical ...

Insights show patients with non-muscle invasive bladder cancer want to explore new treatment options, yet fewer than one in five say their doctors discuss all available procedures/treatments at most ...